Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975958 · ClinicalTrials.gov registry record · Phase 1
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Adlai Nortye Biopharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04975958 is a Phase 1 study that has completed, run by Adlai Nortye Biopharma Co.. The registered enrollment target is 47 participants.
The verdict
NCT04975958, a Phase 1 study, has completed, sponsored by Adlai Nortye Biopharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.
Interventions
- DRUG AN0025
- DRUG AN2025
- DRUG Atezolizumab 1200 mg in 20 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975958
The ClinicalTrials.gov registry entry for NCT04975958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adlai Nortye Biopharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AN0025 is the first listed.
NCT04975958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04975958 about?
NCT04975958 is a clinical study titled "Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors". This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.
What is the current status of trial NCT04975958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2021-09-07. Estimated completion is 2025-01-24.
What interventions are being tested in trial NCT04975958?
The interventions under investigation include: AN0025 (DRUG), AN2025 (DRUG), Atezolizumab 1200 mg in 20 ML Injection (DRUG).
Who is sponsoring clinical trial NCT04975958?
This trial is sponsored by Adlai Nortye Biopharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.